{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:12:53Z","timestamp":1785787973688,"version":"3.56.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T00:00:00Z","timestamp":1409097600000},"content-version":"vor","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.jacc.2013.05.024","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T02:32:04Z","timestamp":1370572324000},"page":"777-781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The ATLAS ACS 2\u2013TIMI 51 Trial and the Burden of Missing Data"],"prefix":"10.1016","volume":"62","author":[{"given":"Mori J.","family":"Krantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.05.024_bib1","first-page":"e2","article-title":"Heart disease and stroke statistics\u20142012 update: a report from the American Heart Association","volume":"125","author":"Rooger","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.05.024_bib2","first-page":"349","article-title":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.05.024_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"Jneid","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.05.024_bib4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.thromres.2011.03.011","article-title":"Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?","volume":"128","author":"Skeppholm","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2013.05.024_bib5","unstructured":"U.S. Food and Drug Administration. May 23, 2012, Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/ucm285415.htm. Accessed November 13,\u00a02012."},{"key":"10.1016\/j.jacc.2013.05.024_bib6","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Approval Package for Application Number 202439Orig1s000. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202439Orig1s000Approv.pdf. Accessed November 13,\u00a02012."},{"key":"10.1016\/j.jacc.2013.05.024_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.05.024_bib8","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.05.024_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.05.024_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.05.024_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","author":"Oldgren","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.05.024_bib12","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry-Providing Evidence of Effectiveness for Human Drug and Biological Products. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm078749.pdf. Accessed November 13,\u00a02012."},{"key":"10.1016\/j.jacc.2013.05.024_bib13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(02)07882-0","article-title":"Sample size slippages in randomised trials: exclusions and the lost and wayward","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.05.024_bib14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2005.09.060","article-title":"A\u00a0comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes","volume":"47","author":"Rao","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.05.024_bib15","unstructured":"Marciniak TA, for the U.S. Food and Drug Administration. NDA 202-439: Rivaroxaban for Acute Coronary Syndromes. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM305921.pdf. Accessed November 13,\u00a02012."},{"key":"10.1016\/j.jacc.2013.05.024_bib16","series-title":"The Prevention and Treatment of Missing Data in Clinical Trials","year":"2010"},{"key":"10.1016\/j.jacc.2013.05.024_bib17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jacc.2013.05.024_bib18","unstructured":"FDA again rejects ACS indication for rivaroxaban (Xarelto). Forbes. Available at: http:\/\/www.forbes.com\/sites\/larryhusten\/2013\/03\/04\/fda-again-rejects-acs-indication-for-rivaroxaban-xarelto\/. Accessed March 21,\u00a02013."},{"key":"10.1016\/j.jacc.2013.05.024_bib19","unstructured":"Rivaroxaban gets ACS indication recommendation from European regulators. theheart.org. Available at: http:\/\/www.theheart.org\/article\/1521155.do?utm_medium=email&utm_source=20130322_breaking&utm_campaign=newsletter. Accessed March 22,\u00a02013."},{"key":"10.1016\/j.jacc.2013.05.024_bib20","unstructured":"U.S. Food and Drug Administration. February 3, 2009, Meeting of the Cardiovascular and Renal Drugs Q 4 Advisory Committee. Available at: http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/ucm125999.htm. Accessed March 22, 2013"},{"key":"10.1016\/j.jacc.2013.05.024_bib21","unstructured":"U.S. Food and Drug Administration. Ticagrelor NDA 22\u2013433 Briefing\u00a0Document for Cardiovascular and Renal Drugs Advisory Committee\u00a0Meeting. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM220197.pdf. Accessed March 22,\u00a02013."}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713021645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713021645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:01:26Z","timestamp":1760014886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713021645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0735109713021645"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.05.024","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ATLAS ACS 2\u2013TIMI 51 Trial and the Burden of Missing Data","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}